-
公开(公告)号:US5977074A
公开(公告)日:1999-11-02
申请号:US624407
申请日:1996-03-28
申请人: Barbara Cordell , Daniel Schirlin , Norton P. Peet , Jeffrey N. Higaki , Viviane Van Dorsselaer , Michael R. Angelastro
发明人: Barbara Cordell , Daniel Schirlin , Norton P. Peet , Jeffrey N. Higaki , Viviane Van Dorsselaer , Michael R. Angelastro
IPC分类号: C07C237/22 , C07C271/22 , C07C279/18 , C07D295/215 , C07F5/02 , C07F7/08 , A61K38/05 , C07K1/00
CPC分类号: C07D295/215 , C07C237/22 , C07C271/22 , C07C279/18 , C07F5/025 , C07F7/0818 , C07C2101/08 , C07C2101/14
摘要: This invention relates to compounds and pharmaceutical compositions, and methods for inhibiting or preventing the amyloid protein deposits in the brain which are associated with Alzheimer's disease and aged Down's syndrome patients. More particularly, it relates to the treatment of Alzheimer's disease.
摘要翻译: PCT No.PCT / US94 / 10679 Sec。 371日期:1996年3月28日 102(e)1996年3月28日PCT PCT 1994年9月20日PCT公布。 公开号WO95 / 09838 日期1995年04月13日本发明涉及化合物和药物组合物,以及用于抑制或预防与阿尔茨海默病和老年唐氏综合征患者相关的脑中的淀粉样蛋白沉积物的方法。 更具体地,涉及阿尔茨海默病的治疗。
-
公开(公告)号:US5593857A
公开(公告)日:1997-01-14
申请号:US749446
申请日:1991-08-23
IPC分类号: A61K38/00 , C07K14/475 , C12N15/12 , C07K14/47
CPC分类号: C07K14/475 , A61K38/00
摘要: There are disclosed neurotrophic factors which are capable of being expressed as polypeptides lacking the microheterogeneity associated with a related native-sequence factor, CNTF. Also disclosed are DNA sequences encoding the neurotrophic factors and methods for expressing and recovering the factors as homogeneous polypeptides.
摘要翻译: 已经公开了能够被表达为缺乏与相关天然序列因子CNTF相关的微不同性的多肽的神经营养因子。 还公开了编码神经营养因子的DNA序列和用于表达和恢复因子作为均质多肽的方法。
-
公开(公告)号:US06579689B2
公开(公告)日:2003-06-17
申请号:US09852914
申请日:2001-05-09
IPC分类号: G01N3353
CPC分类号: C12N9/6421 , A61K38/00 , C07K14/4711
摘要: The present invention provides cell-free &ggr;-secretase activity. The method of the invention utilizes a membrane source of APP/&ggr;-secretase mixture in the assay to determine factors that may enhance or decrease enzymatic activity affecting &bgr;-amyloid peptide production. The cell membranes used in the assay may be from cells expressing an endogenous APP or, preferably, cells expressing a recombinant APP. The APP may be full-length or a fragment capable of being proteolytically cleaved by &ggr;-secretase. In addition, the APP expressed in the cells may have one or more mutation, such as a point mutation, small deletion, etc.
摘要翻译: 本发明提供无细胞γ-分泌酶活性。 本发明的方法在测定中利用APP /γ-分泌酶混合物的膜源来确定可能增强或降低影响β-淀粉样蛋白肽生产的酶活性的因素。 用于测定的细胞膜可以来自表达内源性APP的细胞,或者优选表达重组APP的细胞。 APP可以是全长的或能够被γ-分泌酶蛋白水解切割的片段。 此外,细胞中表达的APP可能具有一个或多个突变,例如点突变,小缺失等。
-
4.
公开(公告)号:US20060183160A1
公开(公告)日:2006-08-17
申请号:US11403512
申请日:2006-04-12
申请人: Ziyang Zhong , Barbara Cordell , Diana Quon , Yu-Wang Liu , Qiang Xu , Frauke Schimmoller , Paul Hyslop , Edward Johnstone , Sheila Little , Stephen Queener , Tinggui Yin
发明人: Ziyang Zhong , Barbara Cordell , Diana Quon , Yu-Wang Liu , Qiang Xu , Frauke Schimmoller , Paul Hyslop , Edward Johnstone , Sheila Little , Stephen Queener , Tinggui Yin
IPC分类号: G01N33/53
CPC分类号: C12N9/6478 , A61K38/00 , C07K14/4711 , C12N9/6421 , C12Q1/37 , G01N33/6896 , G01N2500/00
摘要: The invention concerns a novel β-secretase, a method of partially purifying this novel β-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel β-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.
摘要翻译: 本发明涉及一种新颖的β-分泌酶,一种部分纯化该新型β-分泌酶的方法,以及其用于筛选潜在的候选药物对抗阿尔茨海默病和其他神经疾病的测定中的应用。 根据放射灭活分析计算,新型β-分泌酶分别在HEK293细胞膜提取物和人脑样品中具有约32-39kDa或22-26kDa的估计分子量,并且具有约pH6.5〜 7.0。
-
公开(公告)号:US07087399B1
公开(公告)日:2006-08-08
申请号:US09566746
申请日:2000-05-09
申请人: Ziyang Zhong , Barbara Cordell , Diana Hom Quon , Yu-Wang Liu , Qiang Xu , Frauke Schimmöller , Paul Andrew Hyslop , Edward Marion Johnstone , Sheila Parks Little , Steven Wyatt Queener , Tinggui Yin
发明人: Ziyang Zhong , Barbara Cordell , Diana Hom Quon , Yu-Wang Liu , Qiang Xu , Frauke Schimmöller , Paul Andrew Hyslop , Edward Marion Johnstone , Sheila Parks Little , Steven Wyatt Queener , Tinggui Yin
CPC分类号: C12N9/6478 , A61K38/00 , C07K14/4711 , C12N9/6421 , C12Q1/37 , G01N33/6896 , G01N2500/00
摘要: The invention concerns a novel β-secretase, a method of partially purifying this novel β-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel β-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.
摘要翻译: 本发明涉及一种新颖的β-分泌酶,一种部分纯化该新型β-分泌酶的方法,以及其用于筛选潜在的候选药物对抗阿尔茨海默病和其他神经疾病的测定中的应用。 根据放射灭活分析计算,新型β-分泌酶分别在HEK293细胞膜提取物和人脑样品中具有约32-39kDa或22-26kDa的估计分子量,并且具有约pH6.5〜 7.0。
-
公开(公告)号:US06670182B1
公开(公告)日:2003-12-30
申请号:US09027258
申请日:1998-02-20
申请人: Rebecca Pruss , John Huggins , Guy Rautmann , Barbara Cordell , Jan Marian Scardina , Ronald P. Mischak
发明人: Rebecca Pruss , John Huggins , Guy Rautmann , Barbara Cordell , Jan Marian Scardina , Ronald P. Mischak
IPC分类号: C12N506
CPC分类号: G01N33/6896 , G01N2500/04 , G01N2500/10
摘要: The invention relates to the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing. More specifically, the invention relates to in vitro assays capable of identifying or quantifying a 4.2 kDa &bgr;-amyloid protein. The present invention also provides for DNA and protein molecules for the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing.
摘要翻译: 本发明涉及可用于鉴定β-淀粉样蛋白加工抑制剂的真核细胞系的设计,构建和用途。 更具体地,本发明涉及能够鉴定或定量4.2kDaβ-淀粉样蛋白的体外测定。 本发明还提供用于设计,构建和使用可用于鉴定β-淀粉样蛋白加工抑制剂的真核细胞系的DNA和蛋白质分子。
-
公开(公告)号:US06221670B1
公开(公告)日:2001-04-24
申请号:US08821876
申请日:1997-03-21
IPC分类号: G01N3348
CPC分类号: G01N33/6896 , G01N33/5088 , G01N2333/4709 , G01N2800/2821
摘要: The present invention provides methods that can be used to identify &bgr;-amyloid reducing compounds. The present invention is based on the use of organotypic brain slice culturing methods to simultaneously assess the toxicity and &bgr;-amyloid reducing activity of a test compound.
摘要翻译: 本发明提供可用于鉴定β-淀粉样蛋白还原化合物的方法。 本发明基于使用器官型脑切片培养方法来同时评估测试化合物的毒性和β-淀粉样蛋白降低活性。
-
公开(公告)号:US5220013A
公开(公告)日:1993-06-15
申请号:US444118
申请日:1989-11-30
申请人: Phyllis A. Ponte , Barbara Cordell
发明人: Phyllis A. Ponte , Barbara Cordell
CPC分类号: C12N15/86 , C07K14/4711 , C12N15/71 , C12Q1/6883 , G01N33/6896 , A61K2123/00 , A61K38/00 , C12N2710/24143 , C12Q2600/156 , C12Q2600/158 , G01N2800/2821
摘要: DNA sequences encoding the beta-amyloid core protein, and beta-amyloid-related proteins associated with Alzheimer's disease are disclosed. These sequences are used in producing or constructing recombinant beta-amyloid core protein, beta-amyloid-related proteins and recombinant or synthetic immunogenic peptides. These sequences are also used to identify genomic mutations and/or restriction site alterations which are associated with a predisposition to Alzheimer's disease, for purposes of genetic screening. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
摘要翻译: 公开了编码β-淀粉样蛋白核心蛋白的DNA序列和与阿尔茨海默病相关的β-淀粉样蛋白相关蛋白。 这些序列用于生产或构建重组β-淀粉样蛋白核心蛋白,β-淀粉样蛋白相关蛋白和重组或合成的免疫原性肽。 为了遗传筛选的目的,这些序列还用于鉴定与阿尔茨海默氏病倾向相关的基因组突变和/或限制性位点改变。 针对重组蛋白产生的抗体或由其衍生的免疫原性肽可用于脑血液或阿尔茨海默病的血清蛋白诊断。
-
公开(公告)号:US20080039461A1
公开(公告)日:2008-02-14
申请号:US11648226
申请日:2006-12-28
申请人: Andrew Protter , Camilla Svensson , Tony Yaksh , Barbara Cordell , Sundeep Dugar
发明人: Andrew Protter , Camilla Svensson , Tony Yaksh , Barbara Cordell , Sundeep Dugar
IPC分类号: A61K31/535 , A61K31/415 , A61K31/445 , A61P25/00 , A61K31/505
CPC分类号: A61K31/381 , A61K31/4164 , A61K31/44 , A61K31/496
摘要: The present invention relates to methods for the prevention or treatment of pain by the inhibition of p38 MAP kinase.
摘要翻译: 本发明涉及通过抑制p38 MAP激酶预防或治疗疼痛的方法。
-
公开(公告)号:US5840527A
公开(公告)日:1998-11-24
申请号:US483939
申请日:1995-06-07
IPC分类号: A61K38/00 , C07K14/785 , C12N15/70 , C12N15/85 , C12N1/00 , C12N5/10 , C12N15/12 , C12N15/63
CPC分类号: C07K14/785 , C12N15/70 , C12N15/85 , A61K38/00 , C12N2800/108 , C12N2830/002 , C12N2830/15 , C12N2830/60 , C12N2830/85
摘要: Recombinant materials for the production of low molecular weight hydrophobic lung surfactant proteins are disclosed and claimed. The monomeric forms of the proteins from human and canine sources have apparent molecular weights of about 5 kd and form dimers under some conditions. The availability of these recombinant materials permits production of large amounts of these proteins through recombinant techniques and permits the use of these proteins in pharmaceutical compositions in the treatment of respiratory deficiency syndromes.
摘要翻译: 公开和要求保护用于生产低分子量疏水性肺表面活性蛋白质的重组材料。 来自人和犬源的蛋白质的单体形式具有约5kd的表观分子量,并且在某些条件下形成二聚体。 这些重组材料的可用性允许通过重组技术生产大量的这些蛋白质,并允许在药物组合物中使用这些蛋白质来治疗呼吸缺陷综合征。
-
-
-
-
-
-
-
-
-